Bill > SB3195

This bill mandates that the Department of Human Services must provide coverage for glucagon-like peptide-1 (GLP-1) drugs, which are a class of medications, for weight loss purposes to individuals enrolled in Medicaid and Medicare Part D prescription drug programs, provided the drugs are approved by the U.S. Food and Drug Administration (FDA) for weight loss and prescribed by a qualified practitioner, with no prior authorization required. The bill acknowledges that GLP-1 drugs have been used for diabetes but are now recognized for their effectiveness in treating obesity, a significant health issue linked to other chronic diseases, and aims to address the current limited insurance coverage for these medications when used for weight management by removing existing exclusions. To implement these changes, the Department of Human Services is required to establish temporary rules by August 1, 2026, and permanent rules by January 1, 2028, and funds are appropriated to cover the costs associated with this expanded coverage, with the new provisions taking effect on July 1, 2026.

Health and Social Services

https://www.capitol.hawaii.gov/session/measure_indiv.aspx?billtype=SB&billnumber=3195&year=2026